Medicines, elevated
We aspire to make great medicines, reliably and repeatedly. We match compelling disease targets with proven drug approaches, by integrating in-house R&D with leading-edge computational tools. We choose programs we believe have the potential to redefine the treatment of cancer and other serious diseases.
You are what you work on.
We are pragmatic risk-takers. We have a target-centric pipeline that reflects the talents and life experiences of our team. Attrition is built into our preclinical programs so that only our most promising candidates enter human testing.
Medicines in the making
We design no-regrets development candidates against what we believe are the most promising disease targets. Our process involves:
Matchmaking
Inhibitors, protein degraders, and antibody drug conjugates are clinically proven approaches to making new medicines. We have enabled all of these in-house, so we can choose the best approach for each target and disease.
Invention
Challenging targets require hand-built solutions. Critical research is conducted in-house at our U.S. and EU facilities.
Integration
In silico and machine learning models help our scientists understand protein targets on an atomic level, rapidly evolving chemical matter into potential medicines. Experimental results can make better, more predictive models, helping us prioritize what we believe are the best ideas.
Impact
We serve patients with serious diseases across oncology, immunology, and neurology.
Want to learn more?
Making potential medicines is humbling work. The best way to learn what makes us different is to follow along.